APGE
Company Description
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (255.84M) | (182.15M) | (83.98M) | (39.78M) |
| EPS | -4.22 | -3.30 | -1.66 | -0.79 |
| Free Cash Flow | (232.60M) | (172.33M) | (74.93M) | (16.43M) |
| FCF / Share | -3.83 | -3.12 | -1.48 | -0.32 |
| Operating CF | (227.45M) | (171.17M) | (74.76M) | (16.43M) |
| Total Assets | 937.13M | 753.95M | 401.40M | 152.06M |
| Total Debt | 8.85M | 11.83M | 2.03M | 0 |
| Cash & Equiv | 131.55M | 141.79M | 118.32M | 151.89M |
| Book Value | 903.88M | 716.79M | 379.91M | 142.07M |
| Return on Equity | -0.28 | -0.25 | -0.22 | -0.28 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.85M) | (74.11M) | (69.39M) | (65.02M) | (66.10M) | (55.34M) | (67.22M) | (49.02M) | (33.82M) | (32.09M) | (31.73M) | (20.84M) |
| EPS | -1.14 | -1.06 | -1.03 | -1.11 | -1.13 | -0.95 | -1.22 | -0.86 | -0.60 | -0.64 | -0.63 | -0.41 |
| Free Cash Flow | (71.38M) | (55.57M) | (62.75M) | (54.26M) | (62.80M) | (52.79M) | (67.71M) | (43.27M) | (29.35M) | (31.99M) | (29.92M) | (19.88M) |
| FCF / Share | -0.95 | -0.80 | -1.03 | -0.92 | -1.07 | -0.91 | -1.23 | -0.76 | -0.52 | -0.64 | -0.59 | -0.39 |
| Operating CF | (71.38M) | (55.57M) | (62.69M) | (54.26M) | (62.03M) | (48.48M) | (67.71M) | (42.52M) | (29.30M) | (31.64M) | (29.75M) | (19.88M) |
| Total Assets | 1.34B | 1.29B | 937.13M | 626.16M | 657.77M | 714.16M | 753.95M | 776.29M | 800.66M | 823.66M | 401.40M | 426.42M |
| Total Debt | 6.83M | 8.05M | 8.85M | 9.85M | 10.85M | 11.82M | 11.83M | 12.14M | 4.08M | 1.77M | 2.03M | 0 |
| Cash & Equiv | 105.57M | 451.80M | 131.55M | 107.91M | 124.19M | 106.92M | 141.79M | 118.78M | 307.30M | 485.46M | 118.32M | 188.27M |
| Book Value | 1.19B | 1.26B | 903.88M | 586.34M | 619.40M | 673.36M | 716.79M | 734.40M | 773.64M | 801.48M | 379.91M | 409.24M |
| Return on Equity | -0.07 | -0.06 | -0.08 | -0.11 | -0.11 | -0.08 | -0.09 | -0.07 | -0.04 | -0.04 | -0.08 | -0.05 |
